Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure

How to buy Innate Pharma stock

Learn how to easily invest in Innate Pharma stock.

Innate Pharma is a biotechnology business based in the US. Innate Pharma shares (IPHA) are listed on the NASDAQ and all prices are listed in US Dollars. Innate Pharma employs 213 staff and has a trailing 12-month revenue of around $57 million.

How to buy Innate Pharma stock

  1. Open a stock trading account. Use our comparison table or choose from our Top Picks.
  2. Confirm your payment details. Fund your account with a bank transfer, debit card or credit card and take advantage of any signup bonuses.
  3. Search for the stock by name or ticker symbol – IPHA. It's that simple.

Best for low fees

Finder Award

SoFi Invest


  • Trade stocks for $0 and no annual fee
  • Start trading with a $0 minimum deposit
  • Get up to $1,000 when you fund a new account within 30 days

Promoted for easy user experience

Robinhood


  • Commission-free trading
  • Commission-free crypto
  • No minimum account balance

Promoted

tastyworks


  • $0 commissions on stocks and ETFs
  • $0 closing commissions on stock and ETF options
  • Get $200 in US stocks when you open and fund an account with min. $2,000 for 3+ mos.

Innate Pharma stock price (NASDAQ: IPHA)

Use our graph to track the performance of IPHA stocks over time.

Innate Pharma shares at a glance

Information last updated 2023-01-26.
Latest market close$3.45
52-week range$1.90 - $4.10
50-day moving average $2.77
200-day moving average $2.68
Wall St. target price$8.06
PE ratio N/A
Dividend yield $0 (0%)
Earnings per share (TTM) $-0.69

Buy Innate Pharma stocks from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
1 - 5 of 5
Name Product Available asset types Stock trade fee Minimum deposit Signup bonus
SoFi Invest
Stocks, Options, ETFs, Cryptocurrency
$0
$0
Get up to $1,000
when you fund a new account within 30 days.
Winner of Finder’s Best Low-Cost Broker award.
Robinhood
Stocks, Options, ETFs, Cryptocurrency
$0
$0
Get a free stock
when you successfully sign up and link your bank account.
Make unlimited commission-free trades, plus earn 4% interest on uninvested cash in your account with Robinhood Gold.
tastyworks
Stocks, Options, ETFs, Cryptocurrency
$0
$0
Get $200 in US stocks
when you open and fund an account with min. $2,000 for 3+ mos.
Highly commended for Best Derivatives Trading Platform award.
Public.com
Stocks, ETFs, Cryptocurrency, Alternatives
$0
$0
Get up to $300 in either stocks or crypto
when you use code FINDERUS to sign up and fund a new account.
Trade stocks and ETFs commission-free, plus gain access to alternative investments like art, NFTs and more.
Interactive Brokers
Stocks, Bonds, Options, Mutual funds, ETFs, Cryptocurrency, Futures, Forex
$0
$0
N/A
Winner of Finder’s Best Overall Stock Broker award.
loading

Compare up to 4 providers

*Signup bonus information updated weekly.

Information on this page is for educational purposes only. Finder is not an advisor or brokerage service, and we don't recommend investors to trade specific stocks or other investments.

Finder is not a client of any featured partner. We may be paid a fee for referring prospective clients to a partner, though it is not a recommendation to invest in any one partner.

Is it a good time to buy Innate Pharma stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Innate Pharma price performance over time

Historical closes compared with the close of $3.45 from 2023-01-27

1 week (2023-01-23) -1.71%
1 month (2022-12-30) -7.51%
3 months (2022-10-28) 60.47%
6 months (2022-07-29) 7.81%
1 year (2022-01-28) -3.90%
2 years (2021-01-29) -15.65%
3 years (2020-01-30) 6.9
5 years (2018-01-26) N/A

Innate Pharma financials

Revenue TTM $57 million
Gross profit TTM $-22,301,000
Return on assets TTM -4.3%
Return on equity TTM -17.31%
Profit margin -39.99%
Book value $1.46
Market capitalisation $302.8 million

TTM: trailing 12 months

Innate Pharma share dividends

We're not expecting Innate Pharma to pay a dividend over the next 12 months.

Innate Pharma share price volatility

Over the last 12 months, Innate Pharma's shares have ranged in value from as little as $1.9 up to $4.1. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Innate Pharma's is 0.3569. This would suggest that Innate Pharma's shares are less volatile than average (for this exchange).

Innate Pharma overview

Innate Pharma S. A. , a biotechnology company, discovers, develops, and commercializes therapeutic antibodies for the treatment of oncology indications in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; Avdoralimab (IPH5401), a monoclonal antibody blocking C5a binding to C5aR1 that is in Phase II clinicals trials for the treatment of COVID-19, bullous pemphigoid, chronic spontaneous urticaria, and other inflammatory diseases; IPH5201, a blocking antibody that is in Phase 1 clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; and IPH6101, a NKp46-based NK cell engager for the generation and evaluation of up to two bispecific NK cell engagers. Its products in preclinical trials are IPH43, an anti-MICA/B antibody drug conjugate; Anti-Siglec-9, an antibody program; IPH65, a tetraspecific proprietary antibody; IPH25, a checkpoint inhibitor; and IPH62 and IPH64 programs. Innate Pharma S. A.

Frequently asked questions

What percentage of Innate Pharma is owned by institutions?
Currently 1.178% of Innate Pharma shares are held by institutions.
How many people work for Innate Pharma?
Latest data suggests 213 work at Innate Pharma.
When does the fiscal year end for Innate Pharma?
Innate Pharma's fiscal year ends in December.
Where is Innate Pharma based?
Innate Pharma's address is: 117, Avenue de Luminy, Marseille, France, 13009
What is Innate Pharma's ISIN number?
Innate Pharma's international securities identification number is: US45781K2042
What is Innate Pharma's CUSIP number?
Innate Pharma's Committee on Uniform Securities Identification Procedures number is: 45781K204

More guides on Finder

Ask an Expert

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site